SHANGHAI – BeiGene Co. Ltd. has licensed a second-generation BRAF inhibitor as a promising preclinical candidate oncology drug to Merck KGaA, of Darmstadt, Germany, for the treatment of melanoma, colorectal cancer and other cancers.